ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

LH vs GH // EV/EBITDA & P/E VALUATION

Labcorp Holdings Inc. (NYSE) VS. Guardant Health Inc. (NASDAQ) • 15-METRIC TALLY: LH 9 — GH 4
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (LH VS. GH) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC LH GH SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 28.80% 64.50% -35.70 GH /gross-margins <GO>
Return on Invested Capital (ROIC) 8.30% -17.40% +25.70 LH /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE 19.6x — — TIE /valuation <GO>
Free Cash Flow Yield 4.04% -0.94% +4.98 LH /fcf-yield <GO>
Operating Margin 9.90% -44.50% +54.40 LH /operating-margins <GO>
Net Profit Margin 6.30% -42.40% +48.70 LH /net-margins <GO>
Revenue Growth (YoY) 7.20% 32.90% -25.70 GH /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.81% 0.00% +0.81 LH /dividend-safety <GO>
Altman Z-Score & Debt/Equity 3.58 5.44 -1.86 GH /balance-sheet <GO>
Piotroski F-Score Quality 8/9 6/9 +2.00 LH /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 76.9 62.0 +14.90 LH /rsi-technicals <GO>
10Y Yield & FRED Macro Beta 0.96 0.87 +0.09 LH /macro-sensitivity <GO>
Forward P/E Multiple 31.6x 19.0x +12.60 GH /forward-pe <GO>
Enterprise Scale & Market Cap $29.86B $24.87B $4.99B LH /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR LH REV GH REV LH GROSS % GH GROSS % LH FCF GH FCF
FY 2025 $13.95B $982.0M 28.8% 64.5% $1.21B -$233.1M
FY 2024 $13.01B $739.0M 27.9% 60.8% $1.10B -$274.9M
FY 2023 $12.16B $563.9M — — $780.4M -$350.4M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
LH // BETA 0.96
GH // BETA 0.87